华兰疫苗：重组带状疱疹疫苗（CHO细胞）获药物临床试验批准通知书

Core Viewpoint - Hualan Vaccine has received approval from the National Medical Products Administration for a clinical trial of its recombinant varicella-zoster virus vaccine (CHO cell) [1] Group 1 - The company announced the receipt of the clinical trial approval notice on January 21 [1] - The vaccine is aimed at addressing the varicella-zoster virus, which causes shingles [1] - This approval marks a significant step in the company's vaccine development pipeline [1]